产品
编 号：F742647
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1133766-06-9
产品详情
生物活性：
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity.
体内研究：
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth.Animal Model:Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells
Dosage:30 mg/kg
Administration:IP, twice a week for 2 mouth
Result:Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.
Animal Model:U-87 MG tumor-bearing mice
Dosage:30 mg/kg
Administration:IP, once
Result:Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).
体外研究：
Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET.Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines.
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity.
体内研究：
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth.Animal Model:Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells
Dosage:30 mg/kg
Administration:IP, twice a week for 2 mouth
Result:Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.
Animal Model:U-87 MG tumor-bearing mice
Dosage:30 mg/kg
Administration:IP, once
Result:Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).
体外研究：
Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET.Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备